Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2013 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Viridian Therapeutics, Inc.\DE was $476.33 million, up 28.1% year-over-year; for FY2025, it was $434.24 million, up 45.1% from FY2024.

• Annual Operating Expenses has increased for four consecutive years, with a five-year compound annual growth rate of 31.3% (FY2020 to FY2025).
• In prior years, Viridian Therapeutics, Inc.\DE's Operating Expenses was $299.34 million in FY2024 (+17.5%), $254.76 million in FY2023 (+87.2%), $136.08 million in FY2022 (+64.6%) and $82.69 million in FY2021 (-25.8%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q2 2013.
• On a year-over-year basis, Operating Expenses has increased in each of the last nine quarters, with growth averaging 39.5% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q1 2023, with growth of 178.0%; the weakest was Q4 2021, with a decline of 67.7%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $116.31 million (Q1 2026), $122.88 million (Q4 2025) and $110.58 million (Q3 2025).